AG˹ٷ

STOCK TITAN

[EFFECT] Jaguar Health, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
Rhea-AI Filing Summary

Jaguar Health, Inc. (NASDAQ: JAGX) received SEC notice that its Form S-3 shelf registration statement (File No. 333-288202) became effective on June 27, 2025 at 4:00 p.m. ET. The effectiveness allows the company to register and potentially issue securities in the future without additional SEC review, streamlining capital-raising activities. No financial terms, transaction details, or earnings information were disclosed in the notice.

Jaguar Health, Inc. (NASDAQ: JAGX) ha ricevuto comunicazione dalla SEC che la sua dichiarazione di registrazione a scaffale Form S-3 (File n. 333-288202) è diventata efficace il 27 giugno 2025 alle 16:00 ET. Questa efficacia consente alla società di registrare e potenzialmente emettere titoli in futuro senza ulteriori revisioni da parte della SEC, semplificando le attività di raccolta di capitale. Nel comunicato non sono stati divulgati termini finanziari, dettagli della transazione o informazioni sugli utili.

Jaguar Health, Inc. (NASDAQ: JAGX) recibió aviso de la SEC de que su declaración de registro en estantería Formulario S-3 (Archivo No. 333-288202) se volvió efectiva el 27 de junio de 2025 a las 4:00 p.m. ET. Esta efectividad permite a la empresa registrar y potencialmente emitir valores en el futuro sin revisión adicional de la SEC, agilizando las actividades de recaudación de capital. No se divulgaron términos financieros, detalles de la transacción ni información sobre ganancias en el aviso.

Jaguar Health, Inc. (NASDAQ: JAGX)� SEC로부� Form S-3 선반 등록 서류(파일 번호 333-288202)가 2025� 6� 27� 오후 4�(동부시간)� 효력� 발생했다� 통지� 받았습니�. � 효력 발생으로 회사� 향후 추가 SEC 심사 없이 증권� 등록하고 발행� � 있어 자본 조달 활동� 간소화됩니다. 공지에는 재무 조건, 거래 세부사항 또는 수익 관� 정보가 공개되지 않았습니�.

Jaguar Health, Inc. (NASDAQ : JAGX) a reçu un avis de la SEC indiquant que sa déclaration d'enregistrement en étagère Formulaire S-3 (Dossier n° 333-288202) est devenue effective le 27 juin 2025 à 16h00 ET. Cette prise d'effet permet à la société d'enregistrer et potentiellement d'émettre des titres à l'avenir sans examen supplémentaire de la SEC, facilitant ainsi les activités de levée de fonds. Aucun terme financier, détail de la transaction ou information sur les bénéfices n'a été divulgué dans l'avis.

Jaguar Health, Inc. (NASDAQ: JAGX) erhielt von der SEC die Mitteilung, dass ihre Form S-3 Shelf-Registrierungserklärung (Aktenzeichen 333-288202) am 27. Juni 2025 um 16:00 Uhr ET wirksam wurde. Die Wirksamkeit ermöglicht es dem Unternehmen, Wertpapiere künftig ohne zusätzliche SEC-Prüfung zu registrieren und auszugeben, was die Kapitalbeschaffung vereinfacht. Im Hinweis wurden keine finanziellen Bedingungen, Transaktionsdetails oder Gewinninformationen offengelegt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine shelf S-3 effectiveness; neutral near-term impact.

The SEC EFFECT filing confirms Jaguar Health’s universal shelf registration is now active, giving management flexibility to issue equity, debt, or other securities when market conditions permit. While this can facilitate quicker fundraising, no immediate offering is announced, leaving dilution or leverage implications uncertain. Given the absence of deal size, pricing, or strategic context, the filing is largely administrative and does not materially alter the investment thesis at this stage.

Jaguar Health, Inc. (NASDAQ: JAGX) ha ricevuto comunicazione dalla SEC che la sua dichiarazione di registrazione a scaffale Form S-3 (File n. 333-288202) è diventata efficace il 27 giugno 2025 alle 16:00 ET. Questa efficacia consente alla società di registrare e potenzialmente emettere titoli in futuro senza ulteriori revisioni da parte della SEC, semplificando le attività di raccolta di capitale. Nel comunicato non sono stati divulgati termini finanziari, dettagli della transazione o informazioni sugli utili.

Jaguar Health, Inc. (NASDAQ: JAGX) recibió aviso de la SEC de que su declaración de registro en estantería Formulario S-3 (Archivo No. 333-288202) se volvió efectiva el 27 de junio de 2025 a las 4:00 p.m. ET. Esta efectividad permite a la empresa registrar y potencialmente emitir valores en el futuro sin revisión adicional de la SEC, agilizando las actividades de recaudación de capital. No se divulgaron términos financieros, detalles de la transacción ni información sobre ganancias en el aviso.

Jaguar Health, Inc. (NASDAQ: JAGX)� SEC로부� Form S-3 선반 등록 서류(파일 번호 333-288202)가 2025� 6� 27� 오후 4�(동부시간)� 효력� 발생했다� 통지� 받았습니�. � 효력 발생으로 회사� 향후 추가 SEC 심사 없이 증권� 등록하고 발행� � 있어 자본 조달 활동� 간소화됩니다. 공지에는 재무 조건, 거래 세부사항 또는 수익 관� 정보가 공개되지 않았습니�.

Jaguar Health, Inc. (NASDAQ : JAGX) a reçu un avis de la SEC indiquant que sa déclaration d'enregistrement en étagère Formulaire S-3 (Dossier n° 333-288202) est devenue effective le 27 juin 2025 à 16h00 ET. Cette prise d'effet permet à la société d'enregistrer et potentiellement d'émettre des titres à l'avenir sans examen supplémentaire de la SEC, facilitant ainsi les activités de levée de fonds. Aucun terme financier, détail de la transaction ou information sur les bénéfices n'a été divulgué dans l'avis.

Jaguar Health, Inc. (NASDAQ: JAGX) erhielt von der SEC die Mitteilung, dass ihre Form S-3 Shelf-Registrierungserklärung (Aktenzeichen 333-288202) am 27. Juni 2025 um 16:00 Uhr ET wirksam wurde. Die Wirksamkeit ermöglicht es dem Unternehmen, Wertpapiere künftig ohne zusätzliche SEC-Prüfung zu registrieren und auszugeben, was die Kapitalbeschaffung vereinfacht. Im Hinweis wurden keine finanziellen Bedingungen, Transaktionsdetails oder Gewinninformationen offengelegt.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: June 27, 2025 4:00 P.M.
Form: S-3
CIK: 0001585608
Company Name: Jaguar Health, Inc.
File Number: 333-288202

FAQ

What did Jaguar Health (JAGX) announce in its EFFECT filing?

The SEC declared Jaguar Health’s Form S-3 shelf registration effective on June 27, 2025 at 4:00 p.m. ET.

Does the EFFECT filing mean Jaguar Health is issuing shares immediately?

No. The notice only confirms the shelf is active; no specific securities offering was announced.

Why is a Form S-3 effectiveness important for JAGX investors?

It streamlines future capital raises, allowing Jaguar Health to issue securities quickly when needed.

Were any financial terms or amounts disclosed in the EFFECT filing?

No financial amounts, pricing details, or transaction sizes were provided in the notice.

Could the shelf registration lead to dilution for existing JAGX shareholders?

Potentially, yes—if equity is issued under the shelf, shareholder dilution may occur, though no issuance is currently planned.
Jaguar Health Inc

NASDAQ:JAGX

JAGX Rankings

JAGX Latest News

JAGX Latest SEC Filings

JAGX Stock Data

3.40M
1.17M
14.81%
1.71%
5.81%
Biotechnology
Pharmaceutical Preparations
United States
SAN FRANCISCO